Key terms
About AGRX
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AGRX news
Mar 25
4:35pm ET
Agile Therapeutics announces delisting from Nasdaq
Mar 18
8:10am ET
Agile Therapeutics cut to Hold at Maxim on revenue miss, likely cash needs
Mar 18
7:54am ET
Agile Therapeutics downgraded to Hold from Buy at Maxim
Mar 13
7:37am ET
Agile Therapeutics completes payoff of debt
Feb 24
10:10am ET
Agile Therapeutics Secures Funding Through Warrant Transactions
Feb 22
9:13am ET
Agile Therapeutics announces exercise of warrants for $4.8M gross proceeds
Feb 15
5:07pm ET
Agile Therapeutics Gains Extension on Loan and Nasdaq Compliance
Feb 15
4:50pm ET
Agile Therapeutics granted extension by Nasdaq to regain compliance
Jan 24
1:15pm ET
Buy Rating for Agile Therapeutics: Regulatory Tailwinds and Strong Sales Growth Forecast
Jan 23
9:30am ET
Agile Therapeutics notes Biden administration guidance on contraceptive access
No recent news articles are available for AGRX
No recent press releases are available for AGRX
AGRX Financials
Key terms
Ad Feedback
AGRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AGRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range